Navigation Links
Northwest Bio Reaffirms Its Freedom to Operate; Refutes Other Parties' Misleading Patent Assertions
Date:12/19/2011

imary brain cancer.  It does not include any of the myriad other types of cancers.    

Linda Powers, CEO of Northwest Bio, commented that "We want to correct the misleading statements about patents that have been made by certain parties with a vested interest in slowing us down.  We have confirmed our analysis with patent experts at leading national law firms, and received supporting opinions from them.  We plan to continue correcting misleading statements by other parties, and we urge anyone who is interested in confirming the true facts to review the entire 8-year record of the Cedars Sinai/IMUC '090 patent application process, and the USPTO rejections.  The entire record is publicly available to all online from the USPTO." 

Powers concluded by stating that "We are justifiably confident that we do not infringe the '090 patent, and are prepared to assert all of our rights and remedies.  The '090 patent is neither a barrier nor even a speed bump in the way of our development and future commercialization of DCVax."

About Northwest Biotherapeutics

NW Bio is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis in both the US and Europe.  The Company has a broad platform technology for dendritic cell-based vaccines.  The Company's lead clinical trial is a 240-patient Phase II trial in newly diagnosed Glioblastoma multiforme ("GBM"), the most aggressive and lethal of brain cancer.  The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in multiple other cancers.  The Company has also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer.  For further information
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Northwestern chemists take gold, mass-produce Beijing Olympic logo
2. Northwest Secures US$1.0 Million Debt Financing
3. Northwest Secures US$1.65 Million Debt Financing
4. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
5. Pacific Northwest National Laboratories Becomes a GeneGo Center of Excellence
6. Northwest Biotherapeutics Secures $700,000 Equity Financing
7. Sirius Genomics to Present at Invest Northwest Conference
8. Oncothyreon to present at Invest Northwest 2009
9. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
10. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
11. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... ReliantHeart, Inc., an innovative supplier of advanced mechanical ... transit-time flow measurement solutions, are collaborating on a miniature ... the HeartAssist5® Left Ventricular Assist Device (LVAD). ... and peace of mind. , The Transonic flow ... 1/6th of the power required by earlier flow board ...
(Date:3/26/2015)... 2015 Ale Gicqueau, Founder and President ... Clinical Affairs at Align Technology, on “ Conducting Postmarket ... ACRP 2015 Global Conference and Exhibition on April 25th ... , During the poster presentation, Ale Gicqueau and Victor ... a Postmarket Registry, the requirements and resources to conduct ...
(Date:3/25/2015)... is one of the most attractive in the emerging ... a growing economy and increasing government investment in healthcare, ... Russian market is set to grow at twice the ... around 10-15% annually reaching an approximate market value of ... Green Cross provides total healthcare solutions that ...
(Date:3/25/2015)... TORONTO , March 25, 2015 /PRNewswire/ - SQI Diagnostics ... announced that, as a result of recent discussions with ... common shares of the Company, after dealing with certain ... and special meeting of shareholders on March 26, 2015 ... that the election of directors will take place when ...
Breaking Biology Technology:LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5
... wholly owned subsidiary of British company Innovative Carbon Limited today ... 10th April to 13th. , Graphene, a sheet of carbon ... wonder material. First isolated at Manchester University in 2004, ... race has been on to produce it commercially. To ...
... April 6, 2012 Arteriocyte, a leading biotechnology ... Massachusetts announced today approval from the Food and ... clinical trial using its Magellan MAR01™ technology in ... Device Exemption (IDE 15013) allows Arteriocyte and its ...
... 2012  GenVec, Inc. (NASDAQ:   GNVC) announced publication ... vectors circumvent neutralizing antibodies in order to generate ... published online in PloS ONE, and can be ... "Modification of Ad5 Hexon Hypervariable Regions Circumvents Pre-existing ...
Cached Biology Technology:UK company to demonstrate their commercially effective graphene production process 2Arteriocyte Receives FDA Approval to Initiate Compartment Syndrome Trial for Amputation Prevention Focused on Wounded Warriors 2Arteriocyte Receives FDA Approval to Initiate Compartment Syndrome Trial for Amputation Prevention Focused on Wounded Warriors 3GenVec Announces Research on Improved Vaccine Vectors 2GenVec Announces Research on Improved Vaccine Vectors 3
(Date:3/10/2015)... , March 10, 2015 Transforming ... "Personalized Medicine in Human Space Flight" ... Thomas J. Goodwin , Ph.D. was recently featured by ... past two years. Specifically, "Personalized Medicine in ... scientific papers published in 2013 and 2014 from Springer ...
(Date:3/4/2015)... 2015 Research and Markets ( ... "Global Biometrics Market Forecast and Opportunities, 2020" ... market for biometric authentication systems is projected to ... 2020 The driving forces for this ... government projects and constant development in technology. In ...
(Date:3/2/2015)... Lithuania , March 2, 2015   Neurotechnology ... technologies, today introduced the SentiGaze Software Development Kit ... to create applications that use off-the-shelf webcams to track ... user gazes at a monitor. Heatmaps can be used ... the effectiveness of online advertising. The SDK can also ...
Breaking Biology News(10 mins):"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3
... In evaluating the bioactive compounds of Illinois blueberry ... compounds that inhibit enzymes responsible for carbohydrate absorption and ... help people with diabetes decrease their blood sugar. ... that would optimize the inhibition of the alpha-amylase and ...
... Philadelphia, PA, August 20, 2012 The more that ... The same can be said about the genetics and ... disease, mutation of a single gene predictably produces a ... to Mendelian disorders, understanding bipolar disorder has been extremely ...
... Hillel was named the 2012 recipient of the World ... have advanced human development by improving the quality, quantity, ... Hillela more than 50-year member of the Soil Science ... the 2012 International Annual Meetings of the American Society ...
Cached Biology News:Drink made from berry wine may provide tasty drug for diabetes 2Making sense out of the biological matrix of bipolar disorder 2World Food Prize winner among speakers at agronomy, crop and soil science societies meetings 2World Food Prize winner among speakers at agronomy, crop and soil science societies meetings 3
... The mycobacteria in Complete Freund's adjuvant ... injection site which enhances the immuneresponse. For ... used for the initial injections; Incomplete Freund's ... Antigens (preferably in saline) are typically mixed ...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
Alexa Fluor 350/488/594 Filter Set (Semrock Brightline) *mounted* *Zeiss Axio AF...
...
Biology Products: